Ciclacillin Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Ciclacillin was synthesized by Wyeth Laboratories in 1967 in the course of studies on the improvement of oral absorption of ampicillin. Although its antibacterial activity is one-sixteenth to one-half that of ampicillin, it shows a four to tenfold higher oral absorption and higher urinary excretion. Ciclacillin shows less tendency than ampicillin to cause diarrhea and is used for therapy of pyoderma, wound infection, respiratory and urinary tract infections, as well as ear and nose, and other infections caused by Staphylococcus, Streptococcus, Escherichia coli, Citrobacter, Klebsiella, Proteus, and Haemophilus influenzae.
Verwenden
Antibacterial.
Antimicrobial activity
The structure differs from other aminopenicillins in that the
benzene ring is completely saturated and the amino substituent
is attached directly to it instead of being linked to an
adjacent carbon atom. It is less active than ampicillin against
staphylococci, streptococci and H. influenzae, but is better
absorbed by mouth, peak plasma levels of 10–18 mg/L being
reached after a 500 mg oral dose. Its pharmacokinetic properties,
side effects and use resemble those of ampicillin. It has
limited availability.
Ciclacillin Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
